Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Cerebrospinal Fluid Neurofilament Light Concentration Predicts Brain Atrophy And Cognition In Alzheimer's Disease, Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Ashley I. Bush, Christopher C. Rowe, Colin L. Masters, David Ames, Eugene Hone, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins
Cerebrospinal Fluid Neurofilament Light Concentration Predicts Brain Atrophy And Cognition In Alzheimer's Disease, Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Ashley I. Bush, Christopher C. Rowe, Colin L. Masters, David Ames, Eugene Hone, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins
Research outputs 2014 to 2021
Introduction
This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation.
Methods
CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL).
Results
CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P< .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition.
Discussion
CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.
Detection Of Hfe Haemochromatosis In The Clinic And Community Using Standard Erythrocyte Tests, Niwansa Adris, Simon Hazeldine, Peter Bentley, Debbie Trinder, Anita C.G. Chua, Lawrie W. Powell, Louise E. Ramm, Grant A. Ramm, John K. Olynyk
Detection Of Hfe Haemochromatosis In The Clinic And Community Using Standard Erythrocyte Tests, Niwansa Adris, Simon Hazeldine, Peter Bentley, Debbie Trinder, Anita C.G. Chua, Lawrie W. Powell, Louise E. Ramm, Grant A. Ramm, John K. Olynyk
Research outputs 2014 to 2021
Detection of HFE Haemochromatosis (HH) is challenging in the absence of clinical features. HH subjects have elevated erythrocyte parameters compared to those without HH, but it remains unclear how this could be applied in clinical practice. Thus, we determined the sensitivity, specificity and clinical utility of erythrocyte parameters in 144 HH subjects with (n = 122) or without (n = 22) clinical and/or biochemical expression of iron overload, 1844 general population controls, and 700 chronic disease subjects. For both expressing and non-expressing HH subjects, the mean pre- and post-phlebotomy values of mean cell volume (MCV) and mean cell haemoglobin (MCH) …
Early Diagnosis And Nutritional Treatment Stabilizes Neuropsychiatric Disorders, Ian James Martins
Early Diagnosis And Nutritional Treatment Stabilizes Neuropsychiatric Disorders, Ian James Martins
Research outputs 2014 to 2021
The reliable diagnostic identification of neuropsychiatric disorders such as schizophrenia, bipolar disease, and depression has been associated with some biological markers (genomics, proteomics, metabolomics) but to date, these markers do not have the sensitivity/specificity of a diagnostic test. Biomarker tests that are relevant to global chronic disease are now applicable to neuropsychiatric diseases to prevent autoimmune disease, endoplasmic reticulum stress associated mitophagy with relevance to neuron apoptosis. Metabolic abnormalities has been linked to neuropsychiatric disorder with the careful nutritional assessment of patients reported in many published studies. Early interventions with genomic medicine now assist in the prevention of autoimmune disease …
Biomarkers Of Alzheimer's Disease Risk In Peripheral Tissues; Focus On Buccal Cells, Maxime François, Wayne Leifert, Ralph Martins, Philip Thomas, Michael Fenech
Biomarkers Of Alzheimer's Disease Risk In Peripheral Tissues; Focus On Buccal Cells, Maxime François, Wayne Leifert, Ralph Martins, Philip Thomas, Michael Fenech
Research outputs 2014 to 2021
Alzheimer's disease (AD) is a progressive degenerative disorder of the brain and is the most common form of dementia. To-date no simple, inexpensive and minimally invasive procedure is available to confirm with certainty the early diagnosis of AD prior to the manifestations of symptoms characteristic of the disease. Therefore, if population screening of individuals is to be performed, more suitable, easily accessible tissues would need to be used for a diagnostic test that would identify those who exhibit cellular pathology indicative of mild cognitive impairment (MCI) and AD risk so that they can be prioritized for primary prevention. This need …